CHARACTERIZING PREDNISONE REGIMENS
FOR TREATMENT OF CARDIAC SARCOIDOSIS
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INTRODUCTION

RESULTS

Corticosteroids are the mainstay treatment for
cardiac sarcoidosis (CS), which manifests clinically
in about 5% of sarcoid patients. Current
comparisons of steroid regimens in CS focus on
starting dose and rarely describe taper rates or
expected cumulative exposure. This study
characterizes several prednisone regimens for CS
to strengthen frameworks for defining treatment
goals.

The interaction term was a significant predictor of
both cumulative dose (F4, 4992 = 259.04, p <
0.0001) and taper rate (F4, 4992 = 254.26, p <
0.0001). Cumulative exposure over 52 weeks
(mean±SD) increased proportionally with starting
dose: HD (10.3±3.6 g) vs. MD (6.8±2.7 g), p <
0.0001, HD vs. LD (5.4±2.4 g), p < 0.0001, and
MD vs. LD, p = 0.0064. Taper rate (mean±SD) was
inversely proportional to starting dose: HD
(-0.764±4.19 mg/week) vs. MD (-0.532±3.44
mg/week), p < 0.0001, HD vs. LD (-0.202±3.16
mg/week), p < 0.0001, and MD vs. LD, p <
0.0001.

METHOD
We queried a registry of 1,403 patients referred
to the Hospital of the University of Pennsylvania
for positron emission tomography (PET)
investigation of CS. We performed chart review
of 98 patients with myocardial inflammation on
initial PET who were treatment-naïve, initiated on
prednisone for CS between 2008 and 2019, and
whose dose was known throughout a 52-week
period following treatment initiation. 65.3% of
the patients were male (n = 64) and 27.6% were
female (n = 27). Mean age was 53±9 years.
Patients were stratified by starting dose into lowdose (LD, n = 22) (<30 mg/day), moderate-dose
(MD, n = 52) (30-49 mg/day), and high-dose (HD,
n = 24) (≥50 mg/day) groups. Linear mixed
models were fit for both cumulative dose and
taper rate and included fixed effects for the
interaction between week number with a
quadratic term and starting dose bin. A random
intercept term was included per patient to
account for correlated repeated measures.
ANOVA was performed on both models to
assess the effect of the interaction term. Degrees
of freedom were calculated using Satterthwaite's
method. We performed post-hoc multiplecomparisons analysis of estimated marginal
means to compare taper rates and cumulative
exposure using Tukey’s method. All analyses were
performed using R Statistical Software v4.1.3.

CONCLUSION
Starting dose is related to cumulative exposure
and taper rate. Our models did not account for
disease severity or demographic factors. Future
studies should investigate the association
between cumulative exposure and adverse events
and the relationship between taper rate and
disease relapse.
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